Mecamylamine: Difference between revisions
Gerald Chi (talk | contribs) m (Changed protection level for "Mecamylamine" ([Edit=Allow only autoconfirmed users] (expires 22:16, 21 March 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 22:16, 21 March 2014 (UTC)))) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Mecamylamine}} | ||
{{CMG}}; {{AE}} {{AK}} | |||
}} | |||
{{ | |||
'''''For patient information about Mecamylamine, click [[Mecamylamine (patient information)|here]].''''' | |||
{{SB}} | |||
MECAMYLAMINE<sup>®</sup>, VECAMYL<sup>®</sup> | |||
==Overview== | ==Overview== | ||
'''Mecamylamine''' is a [[nicotinic]] [[antagonist]] that is well absorbed from the [[gastrointestinal tract]] and crosses the [[blood-brain barrier]]. Mecamylamine has been used as a [[ganglionic blocker]] in treating [[hypertension]], but, like most ganglionic blockers, is more often used now as a research tool. | '''Mecamylamine''' is a [[nicotinic]] [[antagonist]] that is well absorbed from the [[gastrointestinal tract]] and crosses the [[blood-brain barrier]]. Mecamylamine has been used as a [[ganglionic blocker]] in treating [[hypertension]], but, like most ganglionic blockers, is more often used now as a research tool. | ||
Mecamylamine is also sometimes used as an anti-addictive drug to help people stop smoking tobacco, and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to it blocking [[α3β4]] [[nicotinic receptors]] in the brain. | Mecamylamine is also sometimes used as an anti-addictive drug to help people stop smoking tobacco, and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to it blocking [[α3β4]] [[nicotinic receptors]] in the brain. | ||
==Category== | |||
Ganglion-blocking/nicotinic antagonist. | |||
==FDA Package Insert== | |||
====VECAMYL<sup>®</sup>=== | |||
''' [[Mecamylamine indications and usage|Indications and Usage]]''' | |||
'''| [[Mecamylamine dosage and administration|Dosage and Administration]]''' | |||
'''| [[Mecamylamine dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[Mecamylamine contraindications|Contraindications]]''' | |||
'''| [[Mecamylamine warnings|Warnings]]''' | |||
'''| [[Mecamylamine precautions|Precautions]]''' | |||
'''| [[Mecamylamine adverse reactions|Adverse Reactions]]''' | |||
'''| [[Mecamylamine drug interactions|Drug Interactions]]''' | |||
'''| [[Mecamylamine use in specific populations|Use in Specific Populations]]''' | |||
'''| [[Mecamylamine overdosage|Overdosage]]''' | |||
'''| [[Mecamylamine description|Description]]''' | |||
'''| [[Mecamylamine clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Mecamylamine nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Mecamylamine clinical studies|Clinical Studies]]''' | |||
'''| [[Mecamylamine how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[Mecamylamine patient counseling information|Patient Counseling Information]]''' | |||
'''| [[Mecamylamine labels and packages|Labels and Packages]]''' | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | |||
{{ | {{Reflist|2}} | ||
[[Category: | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 15:09, 10 March 2014
| Mecamylamine |
|---|
| Mecamylamine tablet®, Vecamyl® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Mecamylamine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information about Mecamylamine, click here.
Synonyms / Brand Names: MECAMYLAMINE®, VECAMYL®
Overview
Mecamylamine is a nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Mecamylamine is also sometimes used as an anti-addictive drug to help people stop smoking tobacco, and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to it blocking α3β4 nicotinic receptors in the brain.
Category
Ganglion-blocking/nicotinic antagonist.
FDA Package Insert
=VECAMYL®
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings | Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages [1]
References
- ↑ "VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS]". Retrieved 10 March 2014.